-
Thematic Analysis
NewRNA-Based Drugs and the Impact of COVID-19
This report investigates the past, current and future landscape of RNA-Based drugs, and how the success of the COVID-19 vaccines may have impacted this. High level analysis of the key trends and movements within the pharmaceutical industry in reference to RNA technology is provided, allowing you to identify and discern the key points within this area.
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – RG-6468 in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - RG-6468 in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. RG-6468 in Solid Tumor Drug Details: RG-6468 (RO-7566802) is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – RG-6315 in Inflammation
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - RG-6315 in Inflammation report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. RG-6315 in Inflammation Drug Details: RG-6315 (RO-7303509) is under development for the...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – RG-6315 1 in Systemic Sclerosis (Scleroderma)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - RG-6315 1 in Systemic Sclerosis (Scleroderma) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. RG-6315 1 in Systemic Sclerosis (Scleroderma) Drug Details: RG-6315 is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Runimotamab in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Runimotamab in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Runimotamab in Solid Tumor Drug Details: BTRC-4017A (RG-6194) is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – RG-6035 in Primary Progressive Multiple Sclerosis (PPMS)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - RG-6035 in Primary Progressive Multiple Sclerosis (PPMS) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. RG-6035 in Primary Progressive Multiple Sclerosis (PPMS) Drug Details:...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – MRTX-0902 in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - MRTX-0902 in Solid Tumor report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. MRTX-0902 in Solid Tumor Drug Details: MRTX-0902 is under development for the...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Runimotamab in Gastric Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Runimotamab in Gastric Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Runimotamab in Gastric Cancer Drug Details: BTRC-4017A (RG-6194) is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – RG-6035 in Relapsing Multiple Sclerosis (RMS)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - RG-6035 in Relapsing Multiple Sclerosis (RMS) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. RG-6035 in Relapsing Multiple Sclerosis (RMS) Drug Details: RG-6035 is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Giredestrant in Breast Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Giredestrant in Breast Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Giredestrant in Breast Cancer Drug Details: GDC-9545 (RG-6171) is under development...